You’re using a public version of DrugChatter with 10 free searches available. Register to unlock more free searches per day. CREATE FREE ACCOUNT

Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.


How long is kadcyla s market exclusivity granted for?

See the DrugPatentWatch profile for kadcyla

Kadcyla, a medication used to treat certain types of breast cancer, has been granted market exclusivity for a specific period. However, the exact duration of this exclusivity is not explicitly stated in the information provided.

The US Food and Drug Administration (FDA) grants market exclusivity to incentivize and protect the investment made by drug manufacturers in the development of new drugs. This exclusivity period begins after a drug receives approval and lasts for a certain number of years, during which no generic versions of the drug can be approved [1].

For oncology drugs like Kadcyla, the exclusivity period can be extended by up to six months if the drug manufacturer conducts pediatric studies [2].

According to, Kadcyla's market exclusivity is set to expire in 2029 [3]. However, it is important to note that this date may change due to various factors, such as patent extensions or legal challenges.

In summary, while the exact duration of Kadcyla's market exclusivity is not explicitly stated, it is expected to last until at least 2029, according to [3].

[1] US Food and Drug Administration. (n.d.). Exclusivity. Retrieved from
[2] US Food and Drug Administration. (n.d.). Pediatric Studies. Retrieved from
[3] (n.d.). Kadcyla (ado-trastuzumab emtansine) - Patent Expiration & Drug Sales. Retrieved from

Other Questions About Kadcyla :  What are the downstream processes for the manufacturing of kadcyla? Are any kadcyla biosimilars currently in development? What are the objectives of the ongoing kadcyla clinical trials?

DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2024. All rights reserved. Privacy